Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ken Kato

Showing results (1-10 of 640) with videos related to

Pageof 64
Sort By:
Nihon Rinsho. Japanese Journal of Clinical Medicine|January 5, 2012
[Development of oral drugs in the standard therapy for metastatic colorectal cancer patients]Ken Kato
Cancer Cell|March 4, 2022
JUPITER-06 establishes immune checkpoint inhibitors as essential first-line drugs for the treatment of advanced esophageal squamous cell carcinomaShun Yamamoto, Ken Kato
Gan to Kagaku Ryoho. Cancer & Chemotherapy|September 19, 2019
[Ⅲ.New Attempt of Chemotherapy for Esophageal Cancer]Masashi Ishikawa, Ken Kato
The New England Journal of Medicine|May 18, 2022
Nivolumab in Esophageal Squamous-Cell Carcinoma. ReplyKen Kato, Ming Lei
Japanese Journal of Clinical Oncology|June 11, 2020
Updates in the 8th edition of the TNM staging system for esophagus and esophagogastric junction cancerHiroyuki Daiko, Ken Kato
Physical Chemistry Chemical Physics : PCCP|February 26, 2024
Theoretical investigation of multi-spin excited states of anthracene radical-linked π-conjugated spin systems by computational chemistryKen Kato, Yoshio Teki
Circulation Journal : Official Journal of the Japanese Circulation Society|July 29, 2016
Documentation of Focal Takotsubo Syndrome and Its Diagnostic Implications　- ReplyKen Kato, Yoshio Kobayashi
Gan to Kagaku Ryoho. Cancer & Chemotherapy|September 22, 2018
[I. Immunotherapy for Esophageal Cancer]Izumi Tanimoto, Ken Kato
Future Oncology (London, England)|August 12, 2020
Immuno-oncology for esophageal cancerShun Yamamoto, Ken Kato
Expert Opinion on Biological Therapy|July 5, 2020
Pembrolizumab for the treatment of esophageal cancerShun Yamamoto, Ken Kato
Pageof 64

Showing results (1-10 of 640) with videos related to

Sort By:
Pageof 64
Nihon Rinsho. Japanese Journal of Clinical Medicine|January 5, 2012
[Development of oral drugs in the standard therapy for metastatic colorectal cancer patients]Ken Kato
Cancer Cell|March 4, 2022
JUPITER-06 establishes immune checkpoint inhibitors as essential first-line drugs for the treatment of advanced esophageal squamous cell carcinomaShun Yamamoto, Ken Kato
Gan to Kagaku Ryoho. Cancer & Chemotherapy|September 19, 2019
[Ⅲ.New Attempt of Chemotherapy for Esophageal Cancer]Masashi Ishikawa, Ken Kato
The New England Journal of Medicine|May 18, 2022
Nivolumab in Esophageal Squamous-Cell Carcinoma. ReplyKen Kato, Ming Lei
Japanese Journal of Clinical Oncology|June 11, 2020
Updates in the 8th edition of the TNM staging system for esophagus and esophagogastric junction cancerHiroyuki Daiko, Ken Kato
Physical Chemistry Chemical Physics : PCCP|February 26, 2024
Theoretical investigation of multi-spin excited states of anthracene radical-linked π-conjugated spin systems by computational chemistryKen Kato, Yoshio Teki
Circulation Journal : Official Journal of the Japanese Circulation Society|July 29, 2016
Documentation of Focal Takotsubo Syndrome and Its Diagnostic Implications　- ReplyKen Kato, Yoshio Kobayashi
Gan to Kagaku Ryoho. Cancer & Chemotherapy|September 22, 2018
[I. Immunotherapy for Esophageal Cancer]Izumi Tanimoto, Ken Kato
Future Oncology (London, England)|August 12, 2020
Immuno-oncology for esophageal cancerShun Yamamoto, Ken Kato
Expert Opinion on Biological Therapy|July 5, 2020
Pembrolizumab for the treatment of esophageal cancerShun Yamamoto, Ken Kato
Pageof 64